Vivimed Labs Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Vivimed Labs.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	18.5%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vivimed Labs has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NSEI:VIVIMEDLAB - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2023	1,733	-3,219	N/A	N/A	N/A
3/31/2023	1,881	-3,285	304	353	N/A
12/31/2022	2,121	-809	N/A	N/A	N/A
9/30/2022	2,124	-862	-6,532	-6,732	N/A
6/30/2022	2,226	-875	N/A	N/A	N/A
3/31/2022	2,386	-676	111	275	N/A
12/31/2021	2,176	-768	N/A	N/A	N/A
9/30/2021	4,438	-1,026	5,200	5,095	N/A
6/30/2021	6,129	-930	N/A	N/A	N/A
3/31/2021	8,713	-719	5,673	5,673	N/A
12/31/2020	10,688	-1,112	N/A	N/A	N/A
9/30/2020	9,863	-937	-218	1,257	N/A
6/30/2020	10,462	-1,064	N/A	N/A	N/A
3/31/2020	10,671	-1,091	-332	796	N/A
12/31/2019	11,828	-485	N/A	N/A	N/A
9/30/2019	12,332	-56	N/A	N/A	N/A
6/30/2019	13,193	391	N/A	N/A	N/A
3/31/2019	13,381	574	3,331	4,221	N/A
12/31/2018	12,727	686	N/A	N/A	N/A
9/30/2018	13,255	787	N/A	N/A	N/A
6/30/2018	12,389	825	N/A	N/A	N/A
3/31/2018	11,953	779	-1,421	214	N/A
12/31/2017	13,377	1,819	N/A	N/A	N/A
9/30/2017	13,978	2,138	N/A	N/A	N/A
6/30/2017	14,131	2,186	N/A	N/A	N/A
3/31/2017	14,700	2,140	N/A	580	N/A
12/31/2016	13,702	1,196	N/A	N/A	N/A
9/30/2016	13,390	903	N/A	N/A	N/A
6/30/2016	13,813	874	N/A	N/A	N/A
3/31/2016	13,456	837	N/A	1,541	N/A
12/31/2015	13,605	890	N/A	N/A	N/A
9/30/2015	13,743	866	N/A	N/A	N/A
6/30/2015	13,510	791	N/A	N/A	N/A
3/31/2015	13,801	721	N/A	1,405	N/A
12/31/2014	14,003	651	N/A	N/A	N/A
9/30/2014	13,918	636	N/A	N/A	N/A
6/30/2014	13,766	635	N/A	N/A	N/A
3/31/2014	13,590	664	N/A	-1,177	N/A
12/31/2013	12,909	703	N/A	N/A	N/A
9/30/2013	12,277	683	N/A	N/A	N/A
6/30/2013	11,889	774	N/A	N/A	N/A
3/31/2013	11,207	836	N/A	901	N/A
12/31/2012	10,640	909	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if VIVIMEDLAB's forecast earnings growth is above the savings rate (6.8%).

Earnings vs Market: Insufficient data to determine if VIVIMEDLAB's earnings are forecast to grow faster than the Indian market

High Growth Earnings: Insufficient data to determine if VIVIMEDLAB's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if VIVIMEDLAB's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if VIVIMEDLAB's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if VIVIMEDLAB's Return on Equity is forecast to be high in 3 years time

Vivimed Labs Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Vivimed Labs Limited to Report Q4, 2024 Results on Sep 06, 2024

Vivimed Labs Limited to Report Q4, 2024 Results on May 20, 2024

Vivimed Labs Limited to Report Nine Months, 2024 Results on Feb 14, 2024

Vivimed Labs Limited to Report Q2, 2024 Results on Nov 14, 2023

Vivimed Labs Limited, Annual General Meeting, Nov 13, 2023

Vivimed Labs Limited to Report Q1, 2024 Results on Aug 14, 2023

Full year 2023 earnings released: ₹39.62 loss per share (vs ₹8.16 loss in FY 2022)

Vivimed Labs Limited to Report Q4, 2023 Results on May 30, 2023

Vivimed Labs Limited, Annual General Meeting, Mar 27, 2023

Third quarter 2023 earnings released

Vivimed Labs Limited, Annual General Meeting, Mar 18, 2023

Less than half of directors are independent

Vivimed Labs Limited to Report Q3, 2023 Results on Feb 13, 2023

Vivimed Labs Limited, Annual General Meeting, Feb 17, 2023

Second quarter 2023 earnings released: ₹2.66 loss per share (vs ₹2.81 loss in 2Q 2022)

Less than half of directors are independent

Vivimed Labs Limited to Report Q2, 2023 Results on Nov 14, 2022

First quarter 2023 earnings released: ₹2.68 loss per share (vs ₹0.28 loss in 1Q 2022)

Vivimed Labs Limited to Report Q1, 2023 Results on Aug 12, 2022

Full year 2022 earnings released: ₹8.16 loss per share (vs ₹9.38 loss in FY 2021)

Vivimed Labs Limited to Report Q4, 2022 Results on May 30, 2022

Less than half of directors are independent

Vivimed Labs Limited Appoints Ramakanta Tripathy as Chief Financial Officer

Is Vivimed Labs (NSE:VIVIMEDLAB) Weighed On By Its Debt Load?

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Vivimed Labs Limited Announces Resignation of Umanath Varahabhotla, as an Independent Director

Vivimed Labs Limited to Report Q3, 2022 Results on Feb 14, 2022

Is Vivimed Labs (NSE:VIVIMEDLAB) Using Too Much Debt?

Second quarter 2022 earnings released: ₹2.81 loss per share (vs ₹1.64 loss in 2Q 2021)

Vivimed Labs Limited announced that it expects to receive INR 21.25 million in funding from Yuga Infratech Private Limited, Procon Power Tech Private Limited, Enviro Green Technologies

First quarter 2022 earnings released: ₹0.28 loss per share (vs ₹1.55 profit in 1Q 2021)

Full year 2021 earnings released: ₹9.38 loss per share (vs ₹13.16 loss in FY 2020)

Estimating The Intrinsic Value Of Vivimed Labs Limited (NSE:VIVIMEDLAB)

Vivimed Labs Limited Receives Approval for 2 Products from Uzbekistan Government for Its PICS & Health Canada

Vivimed's FDF Facility in Jeedimetla Obtained Ukraine GMP Approval(Renewal)

Vivimed Labs Limited Receives Approval for Product

Estimating The Intrinsic Value Of Vivimed Labs Limited (NSE:VIVIMEDLAB)

Third quarter 2021 earnings released: ₹5.99 loss per share (vs ₹3.87 loss in 3Q 2020)

New 90-day low: ₹14.65

Vivimed Labs Limited to Report Q3, 2021 Results on Feb 13, 2021

Did Vivimed Labs Limited (NSE:VIVIMEDLAB) Insiders Buy Up More Shares?

Vivimed Labs Limited Announces Re-Designation of Shri. Ramesh Krishnamurthy as Chief Executive Officer-Cum-Chief Financial Officer, Effective December 4, 2020

Vivimed Labs Limited, Annual General Meeting, Dec 30, 2020

Vivimed Labs Limited Announces the Demise of Prof.Bhagvanth Rao Mamidpalli, an Independent Director

Is Vivimed Labs (NSE:VIVIMEDLAB) Using Too Much Debt?

Vivimed Labs Limited Receives Approvals for 3 Ophthalmic Products from Its Sterile Ophthalmic Facility and 3 Oral Liquid Suspension Products from Its Pics & Health Canada

Vivimed Labs Limited to Report Q2, 2021 Results on Nov 14, 2020

Santosh Varalwar acquired an additional 0.5% stake in Vivimed Labs Ltd. (BSE:532660).

Are Insiders Buying Vivimed Labs Limited (NSE:VIVIMEDLAB) Stock?

First quarter earnings released

Vivimed Labs Limited to Report Q1, 2021 Results on Aug 29, 2020

New 90-day high - ₹15.55

Is Vivimed Labs (NSE:VIVIMEDLAB) Using Debt In A Risky Way?

Vivimed Labs Limited to Report Q4, 2020 Results on Jul 25, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies